Target Price | $102.00 |
Price | $72.00 |
Potential | 41.67% |
Number of Estimates | 16 |
16 Analysts have issued a price target GE HealthCare Technologies 2026 . The average GE HealthCare Technologies target price is $102.00. This is 41.67% higher than the current stock price. The highest price target is $115.00 59.72% , the lowest is $86.00 19.44% . | |
A rating was issued by 20 analysts: 14 Analysts recommend GE HealthCare Technologies to buy, 6 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the GE HealthCare Technologies stock has an average upside potential 2026 of 41.67% . Most analysts recommend the GE HealthCare Technologies stock at Purchase. |
16 Analysts have issued a sales forecast GE HealthCare Technologies 2025 . The average GE HealthCare Technologies sales estimate is $20.0b . This is 1.67% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $20.3b 3.33% , the lowest is $19.9b 0.91% .
This results in the following potential growth metrics:
2024 | $19.7b | 0.61% |
---|---|---|
2025 | $20.0b | 1.66% |
2026 | $20.9b | 4.74% |
2027 | $22.0b | 4.92% |
2028 | $23.0b | 4.63% |
12 Analysts have issued an GE HealthCare Technologies EBITDA forecast 2025. The average GE HealthCare Technologies EBITDA estimate is $3.9b . This is 11.50% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $4.1b 18.14% , the lowest is $3.7b 6.01% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $3.5b | 4.06% |
---|---|---|
2025 | $3.9b | 9.33% |
2026 | $4.2b | 8.09% |
2027 | $4.5b | 6.95% |
2028 | $4.8b | 7.62% |
2024 | 17.97% | 3.43% |
---|---|---|
2025 | 19.33% | 7.54% |
2026 | 19.95% | 3.21% |
2027 | 20.33% | 1.90% |
2028 | 20.91% | 2.85% |
10 GE HealthCare Technologies Analysts have issued a net profit forecast 2025. The average GE HealthCare Technologies net profit estimate is $2.1b . This is 3.82% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.4b 18.89% , the lowest is $1.9b 6.45% .
This results in the following potential growth metrics and future Net Margins:
2024 | $2.0b | 43.71% |
---|---|---|
2025 | $2.1b | 3.82% |
2026 | $2.3b | 12.48% |
2027 | $2.7b | 14.80% |
2028 | $3.0b | 13.36% |
2024 | 10.08% | 42.83% |
---|---|---|
2025 | 10.30% | 2.17% |
2026 | 11.06% | 7.38% |
2027 | 12.10% | 9.40% |
2028 | 13.11% | 8.35% |
10 Analysts have issued a GE HealthCare Technologies forecast for earnings per share. The average GE HealthCare Technologies EPS is $4.51 . This is 3.92% higher than earnings per share in the financial year 2024. The highest EPS forecast is $5.16 18.89% , the lowest is $4.06 6.45% .
This results in the following potential growth metrics and future valuations:
2024 | $4.34 | 43.71% |
---|---|---|
2025 | $4.51 | 3.92% |
2026 | $5.07 | 12.42% |
2027 | $5.82 | 14.79% |
2028 | $6.60 | 13.40% |
Current | 16.58 | 44.83% |
---|---|---|
2025 | 15.98 | 3.62% |
2026 | 14.21 | 11.08% |
2027 | 12.37 | 12.95% |
2028 | 10.92 | 11.72% |
Based on analysts' sales estimates for 2025, the GE HealthCare Technologies stock is valued at an EV/Sales of 1.98 and an P/S ratio of 1.65 .
This results in the following potential growth metrics and future valuations:
Current | 2.01 | 19.60% |
---|---|---|
2025 | 1.98 | 1.45% |
2026 | 1.89 | 4.52% |
2027 | 1.80 | 4.69% |
2028 | 1.72 | 4.43% |
Current | 1.67 | 20.95% |
---|---|---|
2025 | 1.65 | 1.64% |
2026 | 1.57 | 4.53% |
2027 | 1.50 | 4.69% |
2028 | 1.43 | 4.43% |
GE HealthCare Technologies...
Analyst | Rating | Action | Date |
---|---|---|---|
Goldman Sachs |
Neutral
➜
Buy
|
Upgrade | Mar 11 2025 |
Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Feb 14 2025 |
Citigroup |
Buy
➜
Buy
|
Unchanged | Feb 13 2025 |
Jefferies |
Hold
➜
Buy
|
Upgrade | Jan 08 2025 |
Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Oct 31 2024 |
Evercore ISI Group |
Outperform
➜
Outperform
|
Unchanged | Oct 01 2024 |
Stifel |
Buy
➜
Buy
|
Unchanged | Sep 30 2024 |
Analyst Rating | Date |
---|---|
Upgrade
Goldman Sachs:
Neutral
➜
Buy
|
Mar 11 2025 |
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Feb 14 2025 |
Unchanged
Citigroup:
Buy
➜
Buy
|
Feb 13 2025 |
Upgrade
Jefferies:
Hold
➜
Buy
|
Jan 08 2025 |
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Oct 31 2024 |
Unchanged
Evercore ISI Group:
Outperform
➜
Outperform
|
Oct 01 2024 |
Unchanged
Stifel:
Buy
➜
Buy
|
Sep 30 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.